No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs

Mads Rasmussen, P. H. Poulsen, A. Treiber, S. Delahaye, A. Tankisi, G. E. Cold, K. Therkelsen, A. Gjedde, J. Astrup

Research output: Contribution to journalArticle

Abstract

Background: The mechanism behind indomethacin-induced cerebral vasoconstriction is incompletely understood. We tested the hypothesis that the mixed endothelin-1 receptor antagonist bosentan would modify or prevent indomethacin-induced reduction of CBF in the anaesthetized pig. Furthermore, we investigated the effect of bosentan on resting CBF and CMRO2. Methods: Twelve pigs were randomized in two groups of six, and received either bosentan and indomethacin (group 1), or placebo and indomethacin (group 2). Anaesthesia was induced with ketamine and midazolam and maintained with fentanyl, nitrous oxide and pancuronium. Baseline measurements of CBF and CMRO2 were performed before intravenous bolus injection of bosentan (10 mg/kg) or placebo (0.9% NaCl). The second CBF and CMRO2 measurement was performed 30 min after administration of bosentan/placebo. A 40-min infusion of indomethacin (0.05 mg/kg/min) was administered and the third CBF and CMRO2 measurement was performed 80 min after administration of bosentan/placebo. Independently, pharmacokinetic data of bosentan were generated in four pigs. Results: In group 1, baseline CBF was 55 ± 7 ml/100 cm3/min. Administration of bosentan i.v. did not change CBF significantly. Indomethacin decreased CBF to 41 ± 5 ml/100 cm3/min (P <0.002). In group 2, baseline CBF was 54 ± 10 ml/100 cm3/min. Placebo did not change CBF while indomethacin decreased CBF significantly to 41 ± 5 ml/100 cm3/min (P <0.002). No significant changes in CMRO2 were observed. In group 2, a significant increase in MABP was observed after administration of indomethacin. No change in MABP was observed in the bosentan-treated animals. Total plasma concentrations of bosentan at the time of the first and the second PET measurement were 3.9 and 1.4 μg/ml, respectively. The corresponding values for the pharmacologically active metabolite Ro 48-5033 were 1.2 and 0.4 μg/ml. Conclusion: These findings indicate that endothelin receptor stimulation is not involved in indomethacin-induced cerebral vasoconstriction or maintenance of cerebrovascular tone in the anaesthetized pig. However, our results suggest that the increase in MABP is mediated through endothelin receptors.

Original languageEnglish (US)
Pages (from-to)200-207
Number of pages8
JournalActa Anaesthesiologica Scandinavica
Volume47
Issue number2
DOIs
StatePublished - Feb 2003
Externally publishedYes

Fingerprint

Cerebrovascular Circulation
Indomethacin
Swine
Placebos
Endothelin Receptors
Vasoconstriction
Endothelin Receptor Antagonists
bosentan
Pancuronium
Endothelin A Receptors
Midazolam
Nitrous Oxide
Ketamine
Fentanyl
Intravenous Injections

Keywords

  • Bosentan
  • Cerebral blood flow
  • Cerebral metabolic rate of oxygen
  • Endothelin
  • Indomethacin
  • Positron emission tomography

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. / Rasmussen, Mads; Poulsen, P. H.; Treiber, A.; Delahaye, S.; Tankisi, A.; Cold, G. E.; Therkelsen, K.; Gjedde, A.; Astrup, J.

In: Acta Anaesthesiologica Scandinavica, Vol. 47, No. 2, 02.2003, p. 200-207.

Research output: Contribution to journalArticle

Rasmussen, M, Poulsen, PH, Treiber, A, Delahaye, S, Tankisi, A, Cold, GE, Therkelsen, K, Gjedde, A & Astrup, J 2003, 'No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs', Acta Anaesthesiologica Scandinavica, vol. 47, no. 2, pp. 200-207. https://doi.org/10.1034/j.1399-6576.2003.00019.x
Rasmussen, Mads ; Poulsen, P. H. ; Treiber, A. ; Delahaye, S. ; Tankisi, A. ; Cold, G. E. ; Therkelsen, K. ; Gjedde, A. ; Astrup, J. / No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs. In: Acta Anaesthesiologica Scandinavica. 2003 ; Vol. 47, No. 2. pp. 200-207.
@article{89c74fbf2b88477fa7fb7a8104464c15,
title = "No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs",
abstract = "Background: The mechanism behind indomethacin-induced cerebral vasoconstriction is incompletely understood. We tested the hypothesis that the mixed endothelin-1 receptor antagonist bosentan would modify or prevent indomethacin-induced reduction of CBF in the anaesthetized pig. Furthermore, we investigated the effect of bosentan on resting CBF and CMRO2. Methods: Twelve pigs were randomized in two groups of six, and received either bosentan and indomethacin (group 1), or placebo and indomethacin (group 2). Anaesthesia was induced with ketamine and midazolam and maintained with fentanyl, nitrous oxide and pancuronium. Baseline measurements of CBF and CMRO2 were performed before intravenous bolus injection of bosentan (10 mg/kg) or placebo (0.9{\%} NaCl). The second CBF and CMRO2 measurement was performed 30 min after administration of bosentan/placebo. A 40-min infusion of indomethacin (0.05 mg/kg/min) was administered and the third CBF and CMRO2 measurement was performed 80 min after administration of bosentan/placebo. Independently, pharmacokinetic data of bosentan were generated in four pigs. Results: In group 1, baseline CBF was 55 ± 7 ml/100 cm3/min. Administration of bosentan i.v. did not change CBF significantly. Indomethacin decreased CBF to 41 ± 5 ml/100 cm3/min (P <0.002). In group 2, baseline CBF was 54 ± 10 ml/100 cm3/min. Placebo did not change CBF while indomethacin decreased CBF significantly to 41 ± 5 ml/100 cm3/min (P <0.002). No significant changes in CMRO2 were observed. In group 2, a significant increase in MABP was observed after administration of indomethacin. No change in MABP was observed in the bosentan-treated animals. Total plasma concentrations of bosentan at the time of the first and the second PET measurement were 3.9 and 1.4 μg/ml, respectively. The corresponding values for the pharmacologically active metabolite Ro 48-5033 were 1.2 and 0.4 μg/ml. Conclusion: These findings indicate that endothelin receptor stimulation is not involved in indomethacin-induced cerebral vasoconstriction or maintenance of cerebrovascular tone in the anaesthetized pig. However, our results suggest that the increase in MABP is mediated through endothelin receptors.",
keywords = "Bosentan, Cerebral blood flow, Cerebral metabolic rate of oxygen, Endothelin, Indomethacin, Positron emission tomography",
author = "Mads Rasmussen and Poulsen, {P. H.} and A. Treiber and S. Delahaye and A. Tankisi and Cold, {G. E.} and K. Therkelsen and A. Gjedde and J. Astrup",
year = "2003",
month = "2",
doi = "10.1034/j.1399-6576.2003.00019.x",
language = "English (US)",
volume = "47",
pages = "200--207",
journal = "Acta Anaesthesiologica Scandinavica",
issn = "0001-5172",
publisher = "Blackwell Munksgaard",
number = "2",

}

TY - JOUR

T1 - No influence of the endothelin receptor antagonist bosentan on basal and indomethacin-induced reduction of cerebral blood flow in pigs

AU - Rasmussen, Mads

AU - Poulsen, P. H.

AU - Treiber, A.

AU - Delahaye, S.

AU - Tankisi, A.

AU - Cold, G. E.

AU - Therkelsen, K.

AU - Gjedde, A.

AU - Astrup, J.

PY - 2003/2

Y1 - 2003/2

N2 - Background: The mechanism behind indomethacin-induced cerebral vasoconstriction is incompletely understood. We tested the hypothesis that the mixed endothelin-1 receptor antagonist bosentan would modify or prevent indomethacin-induced reduction of CBF in the anaesthetized pig. Furthermore, we investigated the effect of bosentan on resting CBF and CMRO2. Methods: Twelve pigs were randomized in two groups of six, and received either bosentan and indomethacin (group 1), or placebo and indomethacin (group 2). Anaesthesia was induced with ketamine and midazolam and maintained with fentanyl, nitrous oxide and pancuronium. Baseline measurements of CBF and CMRO2 were performed before intravenous bolus injection of bosentan (10 mg/kg) or placebo (0.9% NaCl). The second CBF and CMRO2 measurement was performed 30 min after administration of bosentan/placebo. A 40-min infusion of indomethacin (0.05 mg/kg/min) was administered and the third CBF and CMRO2 measurement was performed 80 min after administration of bosentan/placebo. Independently, pharmacokinetic data of bosentan were generated in four pigs. Results: In group 1, baseline CBF was 55 ± 7 ml/100 cm3/min. Administration of bosentan i.v. did not change CBF significantly. Indomethacin decreased CBF to 41 ± 5 ml/100 cm3/min (P <0.002). In group 2, baseline CBF was 54 ± 10 ml/100 cm3/min. Placebo did not change CBF while indomethacin decreased CBF significantly to 41 ± 5 ml/100 cm3/min (P <0.002). No significant changes in CMRO2 were observed. In group 2, a significant increase in MABP was observed after administration of indomethacin. No change in MABP was observed in the bosentan-treated animals. Total plasma concentrations of bosentan at the time of the first and the second PET measurement were 3.9 and 1.4 μg/ml, respectively. The corresponding values for the pharmacologically active metabolite Ro 48-5033 were 1.2 and 0.4 μg/ml. Conclusion: These findings indicate that endothelin receptor stimulation is not involved in indomethacin-induced cerebral vasoconstriction or maintenance of cerebrovascular tone in the anaesthetized pig. However, our results suggest that the increase in MABP is mediated through endothelin receptors.

AB - Background: The mechanism behind indomethacin-induced cerebral vasoconstriction is incompletely understood. We tested the hypothesis that the mixed endothelin-1 receptor antagonist bosentan would modify or prevent indomethacin-induced reduction of CBF in the anaesthetized pig. Furthermore, we investigated the effect of bosentan on resting CBF and CMRO2. Methods: Twelve pigs were randomized in two groups of six, and received either bosentan and indomethacin (group 1), or placebo and indomethacin (group 2). Anaesthesia was induced with ketamine and midazolam and maintained with fentanyl, nitrous oxide and pancuronium. Baseline measurements of CBF and CMRO2 were performed before intravenous bolus injection of bosentan (10 mg/kg) or placebo (0.9% NaCl). The second CBF and CMRO2 measurement was performed 30 min after administration of bosentan/placebo. A 40-min infusion of indomethacin (0.05 mg/kg/min) was administered and the third CBF and CMRO2 measurement was performed 80 min after administration of bosentan/placebo. Independently, pharmacokinetic data of bosentan were generated in four pigs. Results: In group 1, baseline CBF was 55 ± 7 ml/100 cm3/min. Administration of bosentan i.v. did not change CBF significantly. Indomethacin decreased CBF to 41 ± 5 ml/100 cm3/min (P <0.002). In group 2, baseline CBF was 54 ± 10 ml/100 cm3/min. Placebo did not change CBF while indomethacin decreased CBF significantly to 41 ± 5 ml/100 cm3/min (P <0.002). No significant changes in CMRO2 were observed. In group 2, a significant increase in MABP was observed after administration of indomethacin. No change in MABP was observed in the bosentan-treated animals. Total plasma concentrations of bosentan at the time of the first and the second PET measurement were 3.9 and 1.4 μg/ml, respectively. The corresponding values for the pharmacologically active metabolite Ro 48-5033 were 1.2 and 0.4 μg/ml. Conclusion: These findings indicate that endothelin receptor stimulation is not involved in indomethacin-induced cerebral vasoconstriction or maintenance of cerebrovascular tone in the anaesthetized pig. However, our results suggest that the increase in MABP is mediated through endothelin receptors.

KW - Bosentan

KW - Cerebral blood flow

KW - Cerebral metabolic rate of oxygen

KW - Endothelin

KW - Indomethacin

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=12244293415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244293415&partnerID=8YFLogxK

U2 - 10.1034/j.1399-6576.2003.00019.x

DO - 10.1034/j.1399-6576.2003.00019.x

M3 - Article

VL - 47

SP - 200

EP - 207

JO - Acta Anaesthesiologica Scandinavica

JF - Acta Anaesthesiologica Scandinavica

SN - 0001-5172

IS - 2

ER -